Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values
about
Serum Immunoglobulin G Levels to Porphyromonas gingivalis Peptidylarginine Deiminase Affect Clinical Response to Biological Disease-Modifying Antirheumatic Drug in Rheumatoid ArthritisUse of data from multiple registries in studying biologic discontinuation: challenges and opportunitiesUse of a 12-week observational period for predicting low disease activity at 52 weeks in RA patients treated with abatacept: a retrospective observational study based on data from a Japanese multicentre registry study.Outcome assessments in rheumatoid arthritis.Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis.The ratio of nurse consultation and physician efficiency index of senior rheumatologists is significantly higher than junior physicians in rheumatology residency training: A new efficiency measure in a cohort, exploratory studyEfficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis.Relationship between time-integrated disease activity estimated by DAS28-CRP and radiographic progression of anatomical damage in patients with early rheumatoid arthritis.Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAClinical significance of cartilage biomarkers for monitoring structural joint damage in rheumatoid arthritis patients treated with anti-TNF therapy.Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis.Decreased semaphorin3A expression correlates with disease activity and histological features of rheumatoid arthritis.Blood monocyte chemotactic protein-1 (MCP-1) and adapted disease activity Score28-MCP-1: favorable indicators for rheumatoid arthritis activity.Development of a multi-biomarker disease activity test for rheumatoid arthritisCirculating cytokine profiles and their relationships with autoantibodies, acute phase reactants, and disease activity in patients with rheumatoid arthritis.Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis.Depletion of B-cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritisBiologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan.Patient-centered psoriatic arthritis (PsA) activity assessment by Stockerau Activity Score for Psoriatic Arthritis (SASPA).An observational study of tocilizumab and TNF-α inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safety.Acquired permanent dislocation of the patella in a patient with rheumatoid genu valgum.Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial.Response to 'Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study'.Utility of a novel inflammatory marker, GlycA, for assessment of rheumatoid arthritis disease activity and coronary atherosclerosisHealth-related quality of life and disease activity in rheumatoid arthritisPretreatment Prediction of Individual Rheumatoid Arthritis Patients' Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptor Biomarkers.Association between anti-Porphyromonas gingivalis or anti-α-enolase antibody and severity of periodontitis or rheumatoid arthritis (RA) disease activity in RA.HLA-DRB1 shared epitope genotyping using the revised classification and its association with circulating autoantibodies, acute phase reactants, cytokines and clinical indices of disease activity in a cohort of South African rheumatoid arthritis patiExpression of Semaphorin 4A and its potential role in rheumatoid arthritis.Usefulness of the SF-36 Health Survey in screening for depressive and anxiety disorders in rheumatoid arthritis.Cut-Offs and Response Criteria for the Hospital Universitario La Princesa Index (HUPI) and Their Comparison to Widely-Used Indices of Disease Activity in Rheumatoid ArthritisInfluence of periodontal treatment on rheumatoid arthritis: a systematic review and meta-analysis.Sustained rheumatoid arthritis remission is uncommon in clinical practice.Evaluation of the Safety and Effectiveness of Add-On Tacrolimus in Patients with Rheumatoid Arthritis Who Failed to Show an Adequate Response to Biological DMARDs: The Interim Results of a Specific Drug Use-Results Survey of Tacrolimus.Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition.Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activityThe role of genetic variants in CRP in radiographic severity in African Americans with early and established rheumatoid arthritisRelationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritis.Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritisRetrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2)
P2860
Q28551566-4A8A2694-701C-4A18-96D3-825E12AF6FA4Q30678187-EF31ABCC-84D2-444F-8E9D-81D2AA4622D9Q30863740-E990E32A-A449-4051-85A7-7BB4C4751092Q33440054-9AB62D2E-8C2C-4780-A10C-D233D2B7AA40Q33482833-F1B9C70D-8075-4796-9909-6013F379C635Q33621429-AC25DB6B-0008-4672-AEBB-B00E66E82927Q33638048-8A6C0EA6-CB86-46D9-B8E2-94535612D9D3Q33915665-A7308C22-8937-4D81-BED8-D49602173352Q34269994-06C120F6-CA5A-40A2-93F1-BFEFE4E7C92EQ34281891-20F3D6F9-1067-4958-BED2-430D6943B27DQ34468474-460BD3B3-DF11-486E-B87E-41E84C5EBEA7Q34560081-CBF07D60-6883-43C2-9324-379E489893B3Q34576441-3FDE1B1C-01E5-4BC9-8E44-E946FBD95DF7Q34667793-5A9B48BF-CD4E-492D-AFAD-2A4638FBDE69Q34700316-FCA33414-3A1C-4EE8-B4EB-6725184F8343Q35012157-99DF09FB-132C-42D6-9AE4-30964E9B739FQ35070822-187F3967-29D1-4761-A944-F46F4FD590E3Q35214632-41806BA2-458C-4D78-8075-D6B29FF6BE47Q35372388-5C889AD9-67D3-426F-9DCD-BC810A6C9389Q35415667-1AECAA66-2A22-4D05-883C-EC28D7395A2BQ35543487-9CEA3F2F-4F74-4DF4-97C0-29C39692E97CQ35605424-FB7B544B-6663-481F-B9C0-14C2595F17BAQ35617601-8849F08D-E124-46A2-B619-98B3EBF5EB8DQ35652911-D41A4BB3-C222-4F8F-A4F9-147ED8FFB4ACQ35686104-8272348B-9845-4263-98C6-AB37D03F8194Q35691806-D1D7AAA4-9BCE-4491-96D5-61726BD47BE3Q35743329-0E01CF54-A293-46E8-AD53-7212AC671B00Q35840775-1F4AC917-798E-4414-B2B7-88A8B884D046Q35995299-2918189D-A870-46B7-9B0D-A4D505B85A99Q36027103-2454E550-AC78-4EF7-9456-27DB46184BE5Q36125286-C5A12B81-09CD-4F97-8DBE-7FEBF3C3310DQ36226993-2195B624-DC88-4788-B9E9-A6442D0F42FAQ36245761-D4045C01-47BA-474A-B511-B7B05B6708D5Q36327800-9962DCDE-E13F-448E-BD2A-4B531CBE9F8CQ36414271-D8494867-33D2-4FAA-92DB-35F0542702DFQ36428250-67110EF0-424F-46EE-B230-2FED339956D1Q36447420-F07BA1FF-49C0-436E-A55F-3C7DB5D44683Q36456822-4163318F-2965-49C7-BF7A-A5F66E3689C2Q36492279-F36F21AA-51B6-4C56-8C6E-568B157407F1Q36517701-A8B9ED03-CBBD-45FF-98C2-6B97573A4A71
P2860
Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Comparison of Disease Activity ...... ctive protein threshold values
@ast
Comparison of Disease Activity ...... ctive protein threshold values
@en
type
label
Comparison of Disease Activity ...... ctive protein threshold values
@ast
Comparison of Disease Activity ...... ctive protein threshold values
@en
prefLabel
Comparison of Disease Activity ...... ctive protein threshold values
@ast
Comparison of Disease Activity ...... ctive protein threshold values
@en
P2093
P2860
P356
P1476
Comparison of Disease Activity ...... ctive protein threshold values
@en
P2093
Eisuke Inoue
Hisashi Yamanaka
Masako Hara
Naoyuki Kamatani
Taisuke Tomatsu
P2860
P304
P356
10.1136/ARD.2006.054205
P407
P577
2006-08-22T00:00:00Z